Holen Sie sich die Stockscreener-App
4.37
4.59%
-0.21
Handel nachbörslich:
4.36
-0.010
-0.23%
Schlusskurs vom Vortag:
$4.58
Offen:
$4.58
24-Stunden-Volumen:
11,633
Relative Volume:
0.03
Marktkapitalisierung:
$6.58M
Einnahmen:
$5.18M
Nettoeinkommen (Verlust:
$-7.79M
KGV:
-1.8517
EPS:
-2.36
Netto-Cashflow:
$-4.99M
1W Leistung:
-18.77%
1M Leistung:
-20.69%
6M Leistung:
-21.68%
1J Leistung:
-71.77%
1-Tages-Spanne:
$4.35
$4.65
1-Wochen-Bereich:
$4.03
$5.50
52-Wochen-Spanne:
$3.54
$17.40
Evoke Pharma Inc Stock (EVOK) Company Profile
Firmenname
Evoke Pharma Inc
Sektor
Telefon
858-345-1494
Adresse
420 STEVENS AVENUE, SOLANA BEACH, CA
Vergleichen Sie EVOK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| EVOK | 4.37 | 6.58M | 5.18M | -7.79M | -4.99M | -2.36 |
| ZTS | 176.42 | 79.51B | 9.15B | 2.43B | 2.31B | 4.92 |
| TAK | 13.53 | 42.89B | 30.27B | 1.93B | 3.45B | 0.444 |
| HLN | 9.43 | 42.57B | 14.26B | 1.55B | 0 | 0.3327 |
| TEVA | 16.49 | 18.51B | 16.77B | -959.00M | 1.37B | -2.00 |
| VTRS | 13.00 | 15.37B | 15.24B | -646.50M | 1.88B | 1.53 |
Evoke Pharma Inc Stock (EVOK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-06-22 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2019-03-05 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2018-03-08 | Bestätigt | B. Riley FBR, Inc. | Buy |
| 2017-10-19 | Fortgesetzt | FBR & Co. | Buy |
| 2017-03-16 | Bestätigt | Rodman & Renshaw | Buy |
| 2017-01-30 | Hochstufung | Laidlaw | Neutral → Buy |
| 2017-01-05 | Hochstufung | Rodman & Renshaw | Neutral → Buy |
| 2016-12-23 | Bestätigt | Rodman & Renshaw | Neutral |
| 2016-07-19 | Bestätigt | FBR Capital | Outperform |
| 2016-07-19 | Herabstufung | Noble Financial | Buy → Hold |
| 2016-07-18 | Herabstufung | Rodman & Renshaw | Buy → Neutral |
| 2016-03-16 | Eingeleitet | Northland Capital | Outperform |
| 2016-03-14 | Bestätigt | Ascendiant Capital Markets | Buy |
| 2016-02-17 | Fortgesetzt | FBR Capital | Outperform |
| 2014-12-03 | Bestätigt | MLV & Co | Buy |
| 2014-11-07 | Eingeleitet | MLV & Co | Buy |
| 2014-04-22 | Eingeleitet | Laidlaw | Buy |
| 2013-11-19 | Eingeleitet | Aegis Capital | Buy |
Alle ansehen
Evoke Pharma Inc Aktie (EVOK) Neueste Nachrichten
EVOK (Evoke Pharma) Total Assets : $14.15 Mil (As of Sep. 2024) - GuruFocus.com
Diabetic Gastroparesis Treatment Market: Global Size, Share, - openPR
Altium Capital Management LP Increases Stake in Evoke Pharma Inc - GuruFocus.com
Canopy Growth (CGC) Stock Dives Amid Financial Struggles and Ind - GuruFocus.com
CRON Experiences Significant Stock Dip Amid Market Volatility - GuruFocus.com
Nasal Drug Delivery Technology Market Breakthrough in Patient Care, Projected Market Growth to USD 7.8 Billion by 2031Market Research Intellect - The Malaysian Reserve
By popular demand: SiGMA Europe launches fourth shed - GlobeNewswire Inc.
Evoke Pharma (NASDAQ:EVOK) Coverage Initiated by Analysts at StockNews.com - Defense World
Evoke Pharma Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Evoke Pharma earnings missed by $0.95, revenue fell short of estimates - Investing.com UK
(EVOK) Trading Advice - Stock Traders Daily
Evoke Pharma Reports Q3 2024 Financial Results - TipRanks
Canopy Growth (CGC) Stock Surges 5.2% Amid Industry Movement - GuruFocus.com
Evoke Pharma, Inc. Reports Third Quarter 2024 Financial Results - The Manila Times
BlackLine Announces the Planned Retirement of Chief Financial Officer and Names Successor - The Manila Times
Nantahala Capital Management's Strategic Acquisition in Evoke Ph - GuruFocus.com
Ironwood Pharmaceuticals (IRWD) Sees Stock Surge Amid Positive A - GuruFocus.com
Gastroparesis Drugs Market to Grow by USD 1.42 Billion from 2024-2028, Driven by Rising Diabetes Rates and AI-Driven Market Trend InsightsTechnavio - The Malaysian Reserve
Is Abbott Laboratories (ABT) the Best Pharma Stock to Buy Right Now? - Yahoo Canada Finance
Evoke Pharma, Inc.'s (NASDAQ:EVOK) Shift From Loss To Profit - Yahoo Finance
Evoke Pharma (NASDAQ:EVOK) Earns Sell Rating from Analysts at StockNews.com - Defense World
Global Digestive Health Market Size, Share And Growth Analysis For 2024-2033 - EIN News
Canopy Growth Corporation (CGC) Stock Price, News, Quote & History - Yahoo Finance
Evoke Pharma (FRA:EV0) Enterprise Value : €1.02 Mil (As of Nov. 01, 2024) - GuruFocus.com
Gastroparesis Treatment Market Top Trends and Growth Analysis: - openPR
When Will Evoke Pharma, Inc. (NASDAQ:EVOK) Become Profitable? - Simply Wall St
Why VF Corp Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket - Benzinga
Five things for pharma marketers to know for Tuesday morning - MM+M Online
Evoke Pharma holds Buy rating with $18 target from Laidlaw - Investing.com
S&P 500 Moves Higher; Philips Shares Plunge After Q3 EarningsKoninklijke Philips (NYSE:PHG) - Benzinga
Monte Rosa Therapeutics, Evoke Pharma, and Autonomix Medical: The Top 3 Stocks Capturing Retail Attention - Barchart
Evoke Pharma Shares Soar on Positive Data for Gimoti Nasal Treatment in Diabetic Gastroparesis - Yahoo Finance
What made Evoke Pharma stock more than double on Monday? - Invezz
Crude Oil Tumbles Over 5%; Autonomix Medical Shares Spike Higher - Benzinga
Evoke Pharma Shares Rise 70% on Gimoti Data in GLP-1 Users - MarketWatch
Evoke stock rockets 90% on study of Gimoti in GLP-1 users (NASDAQ:EVOK) - Seeking Alpha
Dow Jumps Over 300 Points; ON Semiconductor Earnings Top ViewsHealthcare Triangle (NASDAQ:HCTI) - Benzinga
Pre-market Movers: EVOK, HCTI, GLUE, MNPR... - RTTNews
Evoke Pharma Stock Is Soaring Monday: What's Going On? - Benzinga
Evoke Pharma reports significant benefits of GIMOTI in DGP study - Investing.com India
Evoke Pharma & EVERSANA Announce Statistically Significant - GlobeNewswire
Evoke Pharma & EVERSANA Announce Statistically Significant Improvement in Patient Outcomes for GLP-1 users with Diabetic Gastroparesis using GIMOTI® - StockTitan
Gastroparesis Drugs Market: Size, Share, Trends, and Forecast for 2024-2033 - openPR
Global Manufacturer and Distributor Chooses Bridgeline's AI-Powered HawkSearch - The Manila Times
Evoke Pharma to Showcase Award-Winning Research at the 2024 American College of Gastroenterology Annual Scientific Meeting - The Manila Times
Evoke Pharma to Showcase Award-Winning Research at the 2024 - GlobeNewswire
Evoke Pharma appoints Benjamin Smeal as new director By Investing.com - Investing.com Canada
Evoke Pharma appoints Benjamin Smeal as new director - Investing.com India
Evoke Pharma Appoints Benjamin Smeal as Director - TipRanks
Evoke Pharma, Inc. Appoints Benjamin Smeal to Serve as Class II Director - Marketscreener.com
Evoke Pharma appoints new board member Ben Smeal - Investing.com India
Finanzdaten der Evoke Pharma Inc-Aktie (EVOK)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.79%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):